KRAS Variant and Tumor Biology
AssigneeYale University
InventorJoanne B. Weidhaas
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods for identifying a subject at risk of developing cancer, predicting the onset of cancer, and predicting a subject's response to chemotherapy/treatment by determining the presence or absence of a SNP in the KRAS oncogene, known as the KRAS variant.
Claims49
A method of identifying a subject or patient at risk for developing an estrogen receptor (ER) and progesterone receptor (PR) negative (ER/PR negative) breast cancer, comprising detecting a mutation in let-7 complementary site LCS6 of human KRAS in a patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, and wherein the presence of the mutation indicates an increased risk of developing the ER/PR negative breast cancer in the subject.
A method of predicting the onset of developing an estrogen receptor (ER) and progesterone receptor (PR) negative (ER/PR negative) breast cancer in a subject or patient at risk for developing breast cancer, comprising detecting a mutation in let-7 complementary site LCS6 of human KRAS in a patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, and wherein the presence of the mutation indicates an earlier onset of developing the ER/PR negative breast cancer.
A method of prognosing a subject or patient with epithelial ovarian cancer (EOC), comprising detecting a mutation in let-7 complementary site LCS6 of human KRAS in a patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, and wherein the presence of the mutation indicates a decreased survival rate when compared to a control.
A method of predicting the response of an epithelial ovarian cancer (EOC) cell to a platinum-based chemotherapy, comprising detecting a mutation in let-7 complementary site LCS6 of human KRAS in a patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, wherein the presence of the mutation indicates a resistance to platinum-based chemotherapy.
A method of prognosing a subject or patient with colorectal cancer (CRC), comprising detecting a mutation in let-7 complementary site LCS6 of human KRAS in a patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, wherein the presence of the mutation indicates a increased survival rate when compared to a control.
A method of predicting the response of a cancer cell to a monoclonal antibody monotherapy, comprising detecting a mutation in let-7 complementary site LCS6 of human KRAS in a patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, and wherein the presence of the mutation indicates a sensitivity to monoclonal antibody monotherapy.
A method of predicting the response of a cancer cell to the combination of a chemotherapy and monoclonal antibody therapy, comprising detecting a mutation in let-7 complementary site LCS6 of human KRAS in a patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, and wherein the presence of the mutation indicates a resistance to the combination.
A method of predicting the an increased risk of vascularization of a tumor, comprising
- (a) detecting a mutation in let-7 complementary site LCS6 of human KRAS in a first patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, and
- (b) determining the expression level of a miRNA selected from the group consisting of miR-23 and miR-27 in a second patient sample,
- wherein the presence of the mutation in (a) and an increase in the expression level of a miRNA in (b) compared to a control indicates transcriptional silencing of an anti-angiogenic gene, thereby predicting the an increased risk of vascularization of the tumor.
A method of predicting an increased survival or proliferation of a cancer cell under hypoxic conditions, comprising
- (a) detecting a mutation in let-7 complementary site LCS6 of human KRAS in a first patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, and
- (b) determining the expression level of a miR-210 miRNA in a second patient sample,
- wherein the presence of the mutation in (a) and an increase in the expression level of the miRNA in (b) compared to a control predicts an increased survival or proliferation of the cancer cell under hypoxic conditions.
A method of predicting an increased survival or proliferation of a cancer cell, comprising
- (a) detecting a mutation in let-7 complementary site LCS6 of human KRAS in a first patient sample, wherein the mutation is a SNP comprising a uracil (U) or thymine (T) to guanine (G) transition at position 4 of LCS6, and
- (b) determining the methylation status of a promoter of a tumor suppressor gene in a second patient sample,
- wherein the presence of the mutation in (a) and an increase in the methylation of a promoter (b) compared to a control predicts an increased survival or proliferation of the cancer cell.
Dependencies are inferred from the claim text.